

Country Demographics <sup>1, 2</sup>	
Total Population (2018) <sup>1</sup>	10,975,920
Urban Population (% of total, 2018) <sup>1</sup>	19.6%
Health expenditure per capita (\$US, 2016) <sup>1</sup>	NR
Health expenditure, total (% of GDP, 2016) <sup>1</sup>	NR
Total births (2013) <sup>2</sup>	406,000
Surviving Infants (2013) <sup>2</sup>	375,000
Life expectancy at birth (years, 2017) <sup>1</sup>	57.3 years
Number of districts (2013) <sup>2</sup>	80


HBsAg Prevalence <sup>3</sup>	
Pre-vaccine HBsAG+ (%)	22.4%

Liver Cancer as Cause of Cancer Death (in Men) <sup>4</sup>	
Year: 2018	Ranking: 3

2018 Country Comparison in African Region (47 Countries) <sup>5</sup>				
	South Sudan	Number of countries with reported coverage	Highest reported coverage in AFR	Lowest reported coverage in AFR
HepB3 <sup>5</sup>	49%	47	99% (Cabo Verde, Seychelles)	25% (Equatorial Guinea)
HepB BD <sup>5</sup>	NR	4	99% (Algeria)	63% (Senegal)

Hepatitis B Immunization Coverage <sup>5</sup>																				
	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	
HepB3 <sup>5</sup>	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	31%	45%	47%	49%	
HepB BD <sup>5</sup>	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	
BCG <sup>5</sup>	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	75%	65%	58%	55%	55%	52%	52%	52%	

South Sudan: HepB3



Abbreviations: NA= not applicable; NR= no report; HepB BD= birth dose within 24 hours; HepB3= at least 3 doses of HepB vaccine; HBsAG= HepB surface antigen. Data Compiled by Asian Liver Center at Stanford University 2019: World DataBank: World Development Indicators database<sup>1</sup>, WHO Immunization Summary: A statistical reference containing data through 2013<sup>2</sup>, WHO Public Health Significance, Targets, Strategies: HBV country profiles<sup>3</sup>, Global Cancer Observatory: Cancer Today-IARC<sup>4</sup>, WHO Vaccine-Preventable Diseases: Monitoring System. 2019 global summary WHO-UNICEF estimates<sup>5</sup>